



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/19	A1	(11) International Publication Number: WO 93/17677 (43) International Publication Date: 16 September 1993 (16.09.93)
(21) International Application Number: PCT/US93/02126 (22) International Filing Date: 8 March 1993 (08.03.93) (30) Priority data: 848,458 9 March 1992 (09.03.92) US 024,728 1 March 1993 (01.03.93) US (71) Applicant: SEPRACOR, INC. [US/US]; 33 Locke Drive, Marlborough, MA 01752 (US). (72) Inventors: YOUNG, James, W. ; 1788 Oak Creek Drive, Apt. 411, Palo Alto, CA 94304 (US). GRAY, Nancy, M. ; 261 DeSimone Drive, Marlborough, MA 01752 (US). WECHTER, William, J. ; 12876 Highview Drive, Redlands, CA 92373 (US).		(74) Agents: MISROCK, S., Leslie et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ANTIPYRETIC AND ANALGESIC METHODS AND COMPOSITIONS CONTAINING OPTICALLY PURE R(-) KETOPROFEN (57) Abstract Methods and compositions are disclosed utilizing optically pure R(-) ketoprofen for the treatment of pain including, but not limited to, pain associated with toothaches, headaches, sprains, joint pain and post-surgical pain, for example dental pain and ophthalmic pain, while substantially reducing adverse effects including, but not limited to, gastrointestinal, renal and hepatic toxicities, and leukopenia, which are associated with the administration of racemic ketoprofen. Optically pure R(-) ketoprofen is also useful in treating pyrexia while substantially reducing the adverse effects associated with the administration of racemic ketoprofen.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MX	Mexico	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

ANTIPYRETIC AND ANALGESIC METHODS AND COMPOSITIONS
CONTAINING OPTICALLY PURE R(-) KETOPROFEN

1. BACKGROUND OF THE INVENTION

5 This invention relates to novel compositions of
matter containing optically pure R(-) ketoprofen. These compositions possess potent activity in treating pain including but not limited to, pain associated
10 with toothaches, headaches, sprains, joint pain and surgical pain, for example dental pain and ophthalmic pain, while substantially reducing adverse effects associated with the administration of the racemic mixture of ketoprofen including but not limited to
15 gastrointestinal, renal and hepatic toxicities, as well as leukopenia. Additionally, these novel compositions of matter containing optically pure R(-) ketoprofen are useful in treating or preventing pyrexia while substantially reducing the adverse
20 effects associated with the administration of the racemic ketoprofen. Also disclosed are methods for treating the above-described conditions in a human while substantially reducing the adverse effects that are associated with the racemic mixture of ketoprofen,
25 by administering the R(-) isomer of ketoprofen to said human.

 The active compound of these compositions and methods is an optical isomer of ketoprofen. Ketoprofen is described in United States Patent No.
30 3,641,127. Chemically, the active compound is the R(-) isomer of 2-(3-benzoylphenyl)propionic acid, hereinafter referred to as R(-) ketoprofen. The term "R(-) isomer of ketoprofen" and particularly the term "R(-) ketoprofen" encompass optically pure and
35 substantially optically pure R(-) ketoprofen.

Ketoprofen, which is the subject of the present invention, is available commercially only as the 1:1 racemic mixture. That is, ketoprofen is available only as a mixture of optical isomers, called enantiomers.

1.1. Steric Relationship and Drug Action


Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these compounds, called stereoisomers, are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric or racemic mixture.

Stereochemical purity is of importance in the field of pharmaceuticals, where 12 of the 20 most prescribed drugs exhibit chirality. A case in point is provided by the L-form of the beta-adrenergic blocking agent, propranolol, which is known to be 100 times more potent than the D-enantiomer.

Furthermore, optical purity is important since certain isomers may actually be deleterious rather than simply inert. For example, it has been suggested that the D-enantiomer of thalidomide was a safe and effective sedative when prescribed for the control of morning sickness during pregnancy, while the

corresponding L-enantiomer has been believed to be a potent teratogen.

Ketoprofen, which is illustrated in Figure I, is a nonsteroidal antiinflammatory drug ("NSAID") which is known to inhibit the biosynthesis of prostaglandins by the inhibition of the cyclooxygenase enzyme which is ubiquitous in mammalian tissues.



Ketoprofen

Figure I

The enantiomers of ketoprofen are disclosed in Yamaguchi et al., *Nippon Yakurigaku Zasshi*. 90: 295-302 (1987). This reference states that the S-enantiomers of 2-arylpropionic acids have 15-300 times higher prostaglandin synthetase inhibitory activities than the R-enantiomers in the rat. Additionally, the S-enantiomer of ketoprofen is disclosed in United States Patent Nos. 4,868,214, 4,962,124, and 4,927,854. Each of these patents alleges that the analgesic activity of ketoprofen resides exclusively in the S(+) enantiomers, an allegation that stands in sharp contrast to the present invention.

The enantiomers of ketoprofen are also disclosed in Abas et al., *J. Pharmacol. Exp. Ther.*, 240: 637-641 (1987). This reference states that R-ketoprofen is metabolically converted to S-ketoprofen in the rabbit.

In man, such inversion has been suggested to occur only to a small extent. See Jamali et al., *J. Pharm. Sci.*, 79: 460-461 (1990). Jamali et al. teach that the pharmacological activity of ketoprofen is assumed
5 to reside in the S-enantiomer and that interconversion of the R-enantiomer to the S-enantiomer is possibly clinically insignificant.

Furthermore, Caldwell et al., *Biochem. Pharmacol.* 37: 105-114 (1988) state that the interconversion of
10 R-2-arylpropionic acids to S-2-arylpropionic acids is a phenomenon that has been suggested to occur for a variety of 2-arylpropionic acids. Caldwell et al. also teach that the combination of chiral inversion and stereoselective metabolism provides for a more
15 rapid clearance of the R-enantiomers of 2-arylpropionic acids. Additionally, Caldwell et al. allege that "at best, the R-isomers function as prodrugs for the therapeutically active S-forms" when the racemic drug is administered and thus add to both
20 the therapeutic and toxic effects of the active S-enantiomers. This reference further contends that "at worst, the R-enantiomers are undesirable impurities in the active drug" causing difficulties due to non-stereoselective toxicity. Thus the reference alleges
25 that the use of only the S-isomers should provide safer and more effective use of this class of drugs.

Similarly, it has been generalized that the pharmacokinetics of the enantiomers of 2-arylpropionic acids are different due, at least in part, to the
30 unidirectional metabolic inversion of the R to the S enantiomer. However, it has been found that this interconversion depends on the particular compound and the particular species in which it is administered. Jamali, *Eur. J. Drug Metabolism Pharmacol.* 13(1): 1-9
35 (1988).

- The racemic mixture of ketoprofen is presently used primarily as an analgesic agent in treating pain, including but not limited to pain associated with toothaches, headaches, sprains, joint pain and
- 5 surgical pain, for example dental pain (e.g., after periodontal surgery) and ophthalmic pain (e.g., after cataract surgery).

- Pain is a common symptom, reflecting either physical (i.e., the result of tissue injury or
- 10 inflammation) or emotional discomfort. Pain is a complex subjective phenomenon comprised of a sensation reflecting real or potential tissue damage, and the affective response this generates. Pain may be classified as either acute or chronic, and it is of a
- 15 variety of particular types. Acute pain is an essential biologic signal of the potential for, or the extent of, tissue injury. In contrast, chronic pain is physically and psychologically debilitating, and it no longer serves its adaptive biologic role. In many
- 20 patients, organic disease may be insufficient to explain the degree of pain. Chronic pain may be associated with conditions including but not limited to osteoarthritis, rheumatoid arthritis, soft tissue pain syndromes, and headaches.

- 25 Pyrexia, or fever, is an elevation in body temperature as a result of infection, tissue damage, inflammation, graft rejection, malignancy or other disease states. The regulation of body temperature requires a delicate balance between the production and
- 30 loss of heat. The hypothalamus regulates the target point at which body temperature is maintained. In fever, this target point is elevated; antipyretic compositions promote its return to a normal level.

- Many of the NSAIDs cause somewhat similar adverse
- 35 effects. These adverse effects include but are not

limited to gastrointestinal, renal and hepatic toxicities. The administration of the racemic mixture of ketoprofen has been found to cause these, as well as other adverse effects. These other adverse effects include but are not limited to increases in bleeding times due to disruption of platelet function (e.g., thrombocytopenia), and prolongation of gestation due to uterine effects.

Further, leukopenia (decreased white cell count in the blood) is a known side effect of NSAIDs. Agranulocytosis is an acute disease caused by a precipitous drop in the number of white blood cells. The leukopenia/agranulocytosis syndrome has been described for several NSAIDs, such as indomethacin, ketoprofen, and ibuprofen. Indeed, such NSAIDs are contraindicated in patients whose immune systems are compromised by HIV infection, chemotherapy, ionizing irradiation, corticosteroids, immunosuppressives, etc. or by such conditions as emphysema, bronchiectasis, diabetes mellitus, leukemia, burns and the like. Although the overall incidence is low, agranulocytosis is a life-threatening syndrome that develops very rapidly. Periodic white-cell counts are therefore of little help in providing early warning of this syndrome.

Thus, it would be particularly desirable to find a compound with the advantages of the racemic mixture of ketoprofen which would not have the aforementioned disadvantages.

2. SUMMARY OF THE INVENTION


It has now been discovered that the optically pure R(-) isomer of ketoprofen (see Figure II below) is a potent analgesic that substantially reduces adverse effects associated with the administration of

the racemic mixtures of ketoprofen, including but not limited to gastrointestinal, renal and hepatic toxicities, increases in bleeding times, leukopenia, and prolongation of gestation. It has also been

5 discovered that these novel compositions of matter containing optically pure R(-) ketoprofen are useful in treating or preventing pyrexia while substantially reducing the above-described adverse effects associated with the administration of racemic

10 ketoprofen. The present invention also includes methods for treating the above-described conditions in a human while substantially reducing the adverse effects that are associated with the racemic mixture of ketoprofen by administering the optically pure R(-)

15 isomer of ketoprofen to said human.



R(-) Ketoprofen

Figure II

3. DETAILED DESCRIPTION OF THE INVENTION

The present invention encompasses a method of eliciting an analgesic effect in a human, while

30 substantially reducing the concomitant liability of adverse effects associated with the administration of racemic ketoprofen, which comprises administering to a human in need of analgesic therapy, an amount of R(-) ketoprofen, or a pharmaceutically acceptable salt

35 thereof, substantially free of its S(+) stereoisomer,

said amount being sufficient to alleviate pain, but insufficient to cause the adverse effects associated with racemic mixture of ketoprofen.

- The present invention also encompasses an
- 5 analgesic composition for the treatment of a human in need of analgesic therapy, which comprises an amount of R(-) ketoprofen, or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer, said amount being sufficient to
- 10 alleviate pain but insufficient to cause the adverse effects associated with racemic ketoprofen.

- The present invention further encompasses a method of treating or preventing pyrexia in a human, while substantially reducing the concomitant liability
- 15 of adverse effects associated with the administration of racemic ketoprofen, which comprises administering to a human an amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer, said
- 20 amount being sufficient to alleviate or prevent said pyrexia but insufficient to cause adverse effects associated with the administration of racemic ketoprofen.

- In addition, the present invention encompasses an
- 25 antipyretic composition for the treatment of a human in need of such therapy which comprises an amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer, said amount being sufficient to alleviate or prevent
- 30 said pyrexia but insufficient to cause adverse effects associated with the administration of racemic ketoprofen.

- The available racemic mixture of ketoprofen (i.e., a 1:1 mixture of the two enantiomers) possesses
- 35 analgesic and antipyretic activity; however, this

racemic mixture while offering the expectation of efficacy, causes adverse effects. Utilizing the substantially optically pure or optically pure R(-) isomer of ketoprofen results in clearer dose related
5 definitions of efficacy, diminished adverse effects, and accordingly, an improved therapeutic index. It is therefore, more desirable to use the R(-) isomer of ketoprofen than racemic ketoprofen.

The term "adverse effects" includes, but is not
10 limited to gastrointestinal, renal and hepatic toxicities, leukopenia, increases in bleeding times due to, e.g., thrombocytopenia, and prolongation of gestation. The term "gastrointestinal toxicities" includes but is not limited to gastric and intestinal
15 ulcerations and erosions. The term "renal toxicities" includes but is not limited to such conditions as papillary necrosis and chronic interstitial nephritis.

In one embodiment the term "substantially free of its S(+) isomer" as used herein means that the
20 composition contains at least 90% by weight of R(-) ketoprofen and 10% by weight or less of the corresponding S(+) ketoprofen. In a preferred embodiment the term "substantially free of the S(+) stereoisomer" means that the composition contains at
25 least 99% by weight of R(-) ketoprofen and 1% or less of the corresponding S(+) ketoprofen. In the most preferred embodiment, the term "substantially free of its S(+) stereoisomer" as used herein means that the composition contains greater than 99% by weight of
30 R(-) ketoprofen and less than 1% of the corresponding S(+) ketoprofen. These percentages are based upon the total amount of ketoprofen present in the composition. The terms "substantially optically pure R(-) isomer of ketoprofen" or "substantially optically pure R(-)
35 ketoprofen" and "optically pure R(-) ketoprofen" or

"optically pure R(-) isomer of ketoprofen" are also encompassed by the above-described amounts.

The term "eliciting an analgesic effect" as used herein means treating, relieving, ameliorating or

- 5 preventing mild to moderate pain. For example, such pain includes but is not limited to pain associated with toothaches, headaches, sprains, joint pain, surgical pain, dental pain, and ophthalmic pain.

- The term "pyrexia" as used herein means the
10 elevation of body temperature brought about by disorders including but not limited to infectious disease, tissue damage, inflammation, graft rejection, malignancy or other disease states.

- The chemical synthesis of the racemic mixture of
15 ketoprofen can be performed by the method described in United States Patent No. 3,641,127 which is hereby incorporated by reference.

- The R(-) isomer of ketoprofen may be obtained from its racemic mixture by resolution of the
20 enantiomers using conventional means such as an optically active resolving base. See, for example, United States Patent Nos. 4,983,765 and 4,973,745, the disclosures of which are incorporated herein by reference. Additionally, the optically pure R-isomer
25 of ketoprofen can be prepared from the corresponding acrylic acid by catalytic hydrogenation using a chiral catalyst. See, for example, European Patent Application No. EP 90/402,433 and WO 90/015,790, the disclosures of which are also incorporated herein by
30 reference. Furthermore, the optically pure R-isomer of ketoprofen can be prepared from the racemic mixture by enzymatic biocatalytic resolution. See, for example, United States Patent Nos. 5,057,427 and 5,077,217, the disclosures of which are incorporated
35 herein by reference.

The magnitude of a prophylactic or therapeutic dose of R(-) ketoprofen in the acute or chronic management of disease will vary with the severity of the condition to be treated, and the route of administration. The dose, and perhaps the dose frequency, will also vary according to the age, body weight, and response of the individual patient. In general, the total daily dose range for R(-) ketoprofen, for the conditions described herein, is from about 25 mg to about 2000 mg, in single or divided doses. Preferably, a daily dose range should be between about 200 mg to about 1000 mg, in single or divided doses. In managing the patient, the therapy should be initiated at a lower dose, perhaps about 25 mg to about 200 mg and increased up to about 1000 mg or higher depending on the patient's global response. It is further recommended that infants, children, patients over 65 years, and those with impaired renal or hepatic function, initially receive low doses, and that they be titrated based on individual response(s) and blood level(s). It may be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art. Further, it is noted that the clinician or treating physician would know how and when to interrupt, adjust or terminate therapy in conjunction with individual patient response. The terms "an amount sufficient to alleviate pain but insufficient to cause said adverse effects" and "an amount sufficient to alleviate or prevent pyrexia but insufficient to cause said adverse effects" are encompassed by the above-described dosage amounts and dose frequency schedule.

Any suitable route of administration may be employed for providing the patient with an effective dosage of R(-) ketoprofen. For example, oral, rectal,

transdermal, parenteral (subcutaneous, intramuscular, intravenous), intrathecal, and like forms of administration may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like.

The pharmaceutical compositions of the present invention comprise R(-) ketoprofen as the active ingredient, or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier, and optionally, other therapeutic ingredients.

The terms "pharmaceutically acceptable salts" or "a pharmaceutically acceptable salt thereof" refer to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. Since the compound of the present invention is acidic, salts may be prepared from pharmaceutically acceptable non-toxic bases including inorganic and organic bases. Suitable pharmaceutically acceptable base addition salts for the compound of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.

The compositions of the present invention include compositions such as suspensions, solutions, elixirs, and aerosols. Carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used in the case of oral solid preparations. Oral solid preparations (such as, powders, capsules, and tablets) are preferred over the oral liquid preparations. The most preferred oral

solid preparation is tablets. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

In addition to the common dosage forms set out
5 above, the compounds of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, the disclosures of which are
10 hereby incorporated by reference in their entireties.

Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays, each containing a
15 predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the
20 methods of pharmacy, but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the
25 active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

For example, a tablet may be prepared by
30 compression or molding, optionally, with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder,
35 lubricant, inert diluent, surface active or dispersing

agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Desirably, each tablet contains from about 12.5 mg to about 1000 mg of the active ingredient, and each cachet or capsule contains from about 12.5 mg to about 600 mg of the active ingredient. Most preferably, the tablet, cachet or capsule contains either one of three dosages, about 50 mg, about 100 mg and about 200 mg of the active ingredient.

The invention is further defined by reference to the following examples describing the preparation of the compositions of the present invention, as well as their utility. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the purpose and interest of this invention.

4. EXAMPLES

20

4.1. EXAMPLE 1

Preparation of R(-) Ketoprofen

The following is a description of the resolution of racemic ketoprofen by an enzymatic process. Included is a description of the synthesis of the water-soluble ester used (a three step procedure), as well as the actual enzymatic resolution, subsequent base hydrolysis, and the recovery of R(-) ketoprofen acid.

30 A. Synthesis of Ketoprofen Dimethylethanolamine Ester

Racemic ketoprofen (0.5 moles) was added to thionyl chloride (1.0 moles) in a flask fitted with a drying tube. Dimethylformamide (0.25 mL) was added to the reaction mixture and the mixture was stirred and warmed until the ketoprofen dissolved and gas

evolution commenced. The heat was removed and the mixture was stirred at room temperature for 18 hours. The thionyl chloride was removed under reduced pressure and the oily residue of acid chloride slowly
5 solidified.

The acid chloride was dissolved in tetrahydrofuran (125 mL) and added to a solution of N,N-dimethylethanolamine (1.0 moles) in tetrahydrofuran (500 mL) cooled to 0° C in a flask
10 equipped with a drying tube. After the addition, the reaction mixture was stirred at room temperature for 18 hours. A saturated aqueous solution of potassium carbonate (500 mL) was added to the reaction mixture and the resulting organic layer was removed. The
15 aqueous layer was extracted with diethyl ether (2X250 mL) and the organic layers were combined, washed with a saturated aqueous solution of sodium chloride, dried over potassium carbonate and the solvent removed under reduced pressure. The product was isolated as a
20 colorless viscous oil.

B. Quaternization of the
N,N-Dimethylethanolamine Ester

The resulting N,N-dimethylethanolamine ester was
25 dissolved in diethyl ether (500 mL) and cooled to 0°C. A solution of dimethyl sulfate (0.36 moles) in diethyl ether (500 mL) was added to the cooled solution and the resulting solution was stirred at room temperature for 18 hours. The resulting solid material was
30 removed by filtration, washed with diethyl ether and dried under vacuum to yield the N,N,N-trimethylethanolammonium ester of ketoprofen (ketoprofen choline ester) as a white solid.

C. Enzymatic Transesterification of the Racemic Ketoprofen Choline Ester

The choline ester (0.36 moles) was dissolved in 0.2 M sodium phosphate buffer (900 ml, pH 7.0). To this solution was added methanol (100 mL) and Protease type XXVII (3 gm) which is available commercially from Sigma Chemical Co. The reaction was allowed to stir gently at room temperature for 24 hours. The reaction mixture was extracted with diethyl ether (2X250mL) and the organic layer was reserved. The aqueous layer was adjusted to pH 2 by the addition of concentrated sulfuric acid and the resulting mixture was washed with ether (2X150 mL). The aqueous layer was concentrated under reduced pressure and the volume was adjusted to 900 mL by the addition of 0.2 M sodium phosphate buffer (pH 7.0). To this solution was added methanol (100 mL) and Protease type XXVII (2 gm). The reaction was allowed to stir gently at room temperature for 24 hours. The reaction mixture was extracted with diethyl ether (2X250mL) and this organic layer was combined with the layer reserved from the first enzymatic reaction. The combined ether layers were dried over magnesium sulfate and the solvent removed under reduced pressure to leave crude R(-) ketoprofen methyl ester, which was dried under vacuum.

D. Preparation of R(-) Ketoprofen

The crude ester was combined with ethanolic potassium hydroxide solution (pH 13) and the resulting mixture was stirred for 1 hour at room temperature.

The resulting solution was adjusted to pH 2 by the addition of hydrochloric acid. The resulting mixture was extracted with diethyl ether and the combined ether solutions were dried over magnesium sulfate and the solvent removed under reduced pressure

to leave crude R(-) ketoprofen. The crude acid was recrystallized from diethyl ether to yield R(-) ketoprofen.

5

4.2. EXAMPLE 2

The phenylquinone writhing test is a standard procedure for detecting and comparing analgesic activity in laboratory animals, and generally correlates well with human efficacy. In response to an injected, locally irritating solution, the animals have cramps ("writhings") that are inhibited by analgesic agents.

Mice were first dosed with at least two dose levels each of R(-) ketoprofen, S(+) ketoprofen, and racemic ketoprofen. The mice were then challenged with a solution of phenyl-p-benzoquinone given intraperitoneally and observed for the characteristic stretch-writhing syndrome. Lack of writhing is indicative of analgesic activity. The degree of analgesic activity was calculated on the basis of suppression of writhing relative to control animals tested the same day. Time response data were obtained by challenging the mice with the phenylquinone solution at different time intervals after dosing them with the test medications.

In this test, 100% of the animals demonstrated at least a 50% reduction in the number of writhings after 30 mg/kg oral dosing with either R(-) ketoprofen or S(+) ketoprofen. All animals were tested one hour after drug administration. The analgesic effects in this test were found to be dose-dependent.

A complicating factor when studying the pharmacological effects of R(-) and S(+) ketoprofen in some animals is that R(-) ketoprofen is inverted into S(+) ketoprofen by a hepatic enzymatic pathway. One

hour after the oral administration of R(-) ketoprofen in mice, approximately 39% of the circulating drug is inverted into the S(+) form. (Such inversion does not occur in man.)

- 5 Since, after one hour (when relatively little inversion had occurred), the analgesic effects of R(-) ketoprofen and S(+) ketoprofen in the writhing test were roughly equivalent, the conclusion may be drawn that R(-) ketoprofen is approximately equipotent with
10 S(+) ketoprofen as an analgesic.

4.3. EXAMPLE 3

Toxicity

- The following is a description of a study of the
15 effects of the isomers of ketoprofen in the guinea pig. Groups of 6-10 guinea pigs are dosed orally with either vehicle, racemic ketoprofen (20, 10, 5, 1 and 0.1 mg/kg), S(+) ketoprofen (20, 10, 5, 1 and 0.1 mg/kg), and R(-) ketoprofen (20, 10, 5, 1 and 0.1
20 mg/kg). Within 24 hours after the dose, the animals are euthanized and gross abnormalities are recorded in the GI tracts, with particular attention to the gastric mucosa of the stomach. Microerosions and redness (irritations) are noted, and the effects are
25 compared between the treatment groups as described by Aberg & Larsson (Acta Pharmacol. Toxicol. 28: 249-257, 1970). Based on such observations, the R(-) isomer is seen to cause virtually no gastrointestinal
30 irritation.

4.4. EXAMPLE 4

Leukopenia

- To test white-cell survival, an *in vitro* test method is used, where a primary bone marrow cell
35 culture is exposed to increasing concentrations of

test compounds such as R(-) ketoprofen and S(+) ketoprofen. A known inducer of leukopenia, such as thiouracil, is used as a positive control. The survival of the granulocytes is measured using
5 conventional differential cell-counting methodology.

The risk for leukopenic effects of escalating concentrations of drugs *in vivo* is studied in groups of animals in which a mild granulocytopenia has initially been induced either by drugs such as
10 thiouracil or chloramphenicol, or by radiation. Repeated white-cell counts are performed to monitor the development of leukopenia in the animals.

15

4.5. EXAMPLE 5

Inhibitory Effect on the Activity of Cyclooxygenase

It is a well-known fact that cyclooxygenase inhibitors (for example aspirin and indomethacin) cause damage and irritation of the gastric mucosa.

20 Assays to determine the inhibitory effect of R(-), S(+), and racemic ketoprofen, reference agents and vehicles on cyclooxygenase activity are conducted using RBL-1 cells (rat basophilic leukemia cell line). The effects of the test compounds, reference agents or
25 vehicles are assessed on the cyclooxygenase-mediated production of $\text{PGF}_{2\alpha}$.

RBL-1 cells are grown in culture in Eagles's minimum essential medium supplemented with 12% fetal bovine serum and 1:100 antibiotic/antimycotic mixture
30 at 37°C. Cells are harvested via centrifugation, washed with cold phosphate buffered saline (PBS), and suspended in PBS supplemented with 0.88 μM CaCl_2 . Cells are incubated in the presence of a screening concentration of test compound or reference agent.

35

Alternatively, cells are incubated in the presence of vehicle.

Following the incubation period, cyclooxygenase activity is stimulated by the addition of 5uM of a calcium ionophore to the incubation medium. The reaction is terminated by chilling the tubes on ice.

The cells are then separated via centrifugation, and the supernatant is removed. Aliquots of the supernatant are used to measure the calcium-ionophore-stimulated production of $\text{PGF}_{2-\alpha}$ via radioimmunoassay.

For each experiment, a vehicle-control is evaluated. A reference standard is also evaluated at a single concentration with each assay.

15

20

25

30

35

4.6. EXAMPLE 6
Oral Formulation

Capsules:

5

Formula	Quantity per capsule in mg		
	A	B	C
Active ingredient			
10 R(-) Ketoprofen	50.0	100.0	200.0
Lactose	48.5	148.5	48.5
Titanium Dioxide	0.5	0.5	0.5
Magnesium Stearate	<u>1.0</u>	<u>1.0</u>	<u>1.0</u>
Compression Weight	100.0	250.0	250.0

15

The active ingredient, R(-) ketoprofen, is sieved and blended with the excipients. The mixture is filled into suitably sized two-piece hard gelatin capsules using suitable machinery. Other doses may be prepared by altering the fill weight and if necessary, changing the capsule size to suit.

20

25

30

35

What is claimed is:

1. A method of eliciting an analgesic effect in a human which comprises administering to a human in need of analgesic therapy, an amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer, said amount being sufficient to alleviate pain.
- 10 2. The method of claim 1 wherein said amount of R(-) ketoprofen is sufficient to alleviate pain but insufficient to cause adverse effects associated with the administration of racemic ketoprofen.
- 15 3. The method of claim 1 wherein R(-) ketoprofen is administered by intrathecal or intravenous infusion, transdermal delivery, or orally as a tablet or a capsule.
- 20 4. The method of claim 3 wherein the amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof administered is from about 25 mg to about 2000 mg per day.
- 25 5. The method of claim 4 wherein the amount administered is from about 200 mg to about 1000 mg per day.
- 30 6. The method of claim 1 wherein the amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total weight of ketoprofen.
- 35 7. The method of claim 1 wherein the amount of said R(-) ketoprofen or a pharmaceutically acceptable

salt thereof, substantially free of the S(+) stereoisomer, is administered together with a pharmaceutically acceptable carrier.

- 5 8. The method of claim 1 wherein R(-) ketoprofen is administered as a salt selected from the group consisting of sodium, calcium and lysinate salts.
- 10 9. An analgesic composition for the treatment of a human in need of analgesic therapy, comprising an amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof, substantially free of the S(+) stereoisomer.
- 15 10. An analgesic composition for the treatment of a human in need of analgesic therapy, which comprises an amount of R(-) ketoprofen, or a pharmaceutically acceptable salt thereof,
- 20 substantially free of the S(+) stereoisomer, said amount being sufficient to alleviate pain, but insufficient to cause adverse effects associated with the administration of racemic ketoprofen.
- 25 11. The composition of claim 9, adapted for oral administration.
12. The composition of claim 9, adapted for parenteral delivery.
- 30 13. The composition of claim 12, further adapted for intramuscular delivery.
14. The composition of claim 9, adapted for
- 35 transdermal delivery.

15. The composition of claim 9, further comprising a pharmaceutically acceptable carrier.

16. The composition of claim 9 wherein R(-)
5 ketoprofen is present as a salt selected from the group consisting of sodium, calcium and lysinate salts.

17. A method of treating or preventing pyrexia
10 in a human which comprises administering to a human an amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer, said amount being sufficient to alleviate or prevent pyrexia.

15

18. The method of claim 17 wherein said amount of R(-) ketoprofen is sufficient to alleviate or prevent said pyrexia but insufficient to cause adverse effects associated with the administration of racemic
20 ketoprofen.

19. The method of claim 17 wherein R(-) ketoprofen is administered by intrathecal or intravenous infusion, transdermal delivery, or orally
25 as a tablet or a capsule.

20. The method of claim 19 wherein the amount of R(-) ketoprofen administered is from about 25 mg to about 2000 mg per day.

30

21. The method of claim 20 wherein the amount administered is from about 200 mg to about 1000 mg per day.

35

22. The method of claim 17 wherein the amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof, is greater than approximately 90% by weight of the total weight of ketoprofen.

5

23. The method of claim 17 wherein the amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof, substantially free of the S(+) stereoisomer, is administered together with a pharmaceutically acceptable carrier.

10

24. The method according to claim 17 wherein R(-) ketoprofen is administered as a salt selected from the group consisting of sodium, calcium and lysinate salts.

15

25. An antipyretic composition for the treatment of a human, comprising an amount of R(-) ketoprofen or a pharmaceutically acceptable salt thereof, substantially free of the S(+) stereoisomer

20

26. The composition of claim 25, adapted for oral administration.

25

27. The composition of claim 25, wherein said composition is adapted for parenteral administration.

28. The composition of claim 27, further adapted for intramuscular delivery.

30

29. The composition of claim 25, adapted for transdermal delivery.

30. The composition of claim 25, further comprising a pharmaceutically acceptable carrier.

35

31. The composition of claim 25 wherein R(-) ketoprofen is present as a salt selected from the group consisting of sodium, calcium and lysinate salts.

5

10

15

20

25

30

35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/02126

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 31/19
US CL : 514/570

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/916

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS and APS- R(-) or levorotary or Lisomer of Ketoprofer as antipyretic or analgesic

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A, 3,641,127, (Farge et al.) 08 February 1972.	1-31
Y	US,A, 4,868,214 (Sunshine et al.) 19 September 1989.	1-31
Y	US,A, 4,962,124, (Sunshine et al.) 19 October 1990.	1-31
A,P	US,A, 5,114,714, (Young et al.) 19 May 1992.	1-31
A,P	US,A, 5,114,715 (Young et al.) 19 May 1992.	1-31
Y	<u>Organic Chemistry</u> , 1987, Wade, L.G. Jr., "Biological Discrimination of Enantiomers", page 349 particularly.	1-31

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be part of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combinations being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 MAY 1993

Date of mailing of the international search report

16 JUN 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

M. MOEZE

PCT/US93-10

Telephone No.

(703) 308-1235